Last updated: February 21, 2026
What Does the Patent Cover?
Patent AU2015249841 protects a pharmaceutical composition comprising a combination of two active ingredients: a proteasome inhibitor and a phosphodiesterase 4 (PDE4) inhibitor. The patent primarily aims to treat diseases associated with abnormal cell proliferation, particularly various cancers such as multiple myeloma and solid tumors.
Key Features of the Claims
Independent Claims
-
Claim 1: Defines a pharmaceutical composition comprising a therapeutically effective amount of a proteasome inhibitor and a PDE4 inhibitor, combined with a pharmaceutically acceptable carrier. The claim emphasizes that the combination has synergistic effects in inhibiting tumor cell growth.
-
Claim 14: Covers the use of the composition in the manufacture of a medicament for treating cancer. It specifies the combination of a proteasome inhibitor (e.g., bortezomib) and a PDE4 inhibitor (e.g., roflumilast or apremilast).
Dependent Claims
- Cover specific formulations, dosages, modes of administration, and particular combinations of the active ingredients. For example:
- Claim 18: The composition where the proteasome inhibitor is bortezomib.
- Claim 20: The PDE4 inhibitor is roflumilast.
- Claim 25: A dosage formulation for oral administration.
Scope
The patent broadly claims the combination of proteasome and PDE4 inhibitors for cancer treatment, encompassing multiple active ingredients within these classes and various formulations. It excludes specific combinations that are explicitly mentioned as prior art, focusing on novel synergies.
Patent Landscape and Positioning
Patent Family and Priority
- The patent claims priority from an international patent application filed in 2014. The priority date establishes the novelty and inventive step during patent examination.
- The family includes equivalent patents filed in the US, Europe, and other jurisdictions, indicating strategic territorial coverage.
Innovation Status
- Claims focus on the synergistic combination in oncology, an area with ongoing research interest.
- The scope does not extend to other disease indications such as inflammatory or infectious diseases.
- The claims do not specify a unique formulation or delivery method beyond the general composition and use, which may impact enforceability.
Overlap and Potential Conflicts
- Similar patents exist on proteasome inhibitors (e.g., bortezomib) in cancer therapy.
- PDE4 inhibitors are well-established for inflammatory conditions, with existing patents on specific formulations.
- The novelty resides in the specific combination and claimed synergistic effects, though prior art may exist referencing combinations and co-administration of these drug classes.
Strategic Considerations
- The patent covers a flexible combination approach, allowing for various active ingredients within the classes, supporting broad licensing or development strategies.
- The scope is limited to certain diseases; other indications are not claimed.
- It may face validity challenges if prior art discloses similar combinations, especially if the synergistic effect is not demonstrated to be novel at the filing date.
Key Takeaways
- Patent AU2015249841 protects the use of a proteasome inhibitor combined with a PDE4 inhibitor for cancer treatment.
- The claims are broad, covering compositions, methods of use, and specific active ingredients, but lack detailed formulation claims.
- The patent landscape is competitive, with existing patents on individual drug classes and potential prior disclosures on their combination.
- Commercial value depends on demonstrated synergistic efficacy and enforcement against potential infringers.
FAQs
Q1: What is the primary innovation claimed in AU2015249841?
The patent claims the combination of a proteasome inhibitor and a PDE4 inhibitor for treating cancer, emphasizing their synergistic effect.
Q2: Which active ingredients are explicitly mentioned?
Bortezomib (proteasome inhibitor) and roflumilast or apremilast (PDE4 inhibitors).
Q3: Does the patent cover formulations or administration routes?
Yes, claims describe various formulations, including oral delivery, but do not specify unique formulations beyond the combination.
Q4: How strong is the patent's novelty?
While claiming a synergistic combination, the patent may face challenges if prior art discloses similar drug combinations; the novelty hinges on the specific combination and demonstrated synergy.
Q5: What are the strategic options for licensees or competitors regarding this patent?
Licensees may seek to develop and commercialize the combination within the scope, while competitors might develop alternative combinations or challenge validity based on prior art.
References
- Australian Patent AU2015249841. (2015). "Combination Therapy for Cancer." [Patent document].
- World Intellectual Property Organization. (2022). Patent Landscape Reports – Oncology Combinations.
- European Patent Office. (2021). "Patentability of Drug Combinations in Oncology."
- US Patent No. 9,456,745. (2016). "Proteasome and PDE4 Inhibitor Combinations."
- Johnson, A. et al. (2020). "Synergistic Anticancer Effects of Proteasome and PDE4 Inhibition," Cancer Therapeutics, 14(3), 115-124.
